AveXis, a Novartis company, announced interim data from ongoing trials of the investigational product Zolgensma or onasemnogene abeparvovec-xioi; AVXS-101 that showed positive results across a broad spectrum of patients with spinal muscular atrophy or SMA.
Source: www.rttnews.com
AveXis, a Novartis company has reported the interim data for ongoing trials of the investigational product Zolgensma (AVXS -101). Zolgensma, is a gene therapy designed to deliver a functional copy of the SMN1 gene to motor neurons in spinal muscle atrophy (SMA). This new product has shown positive results across a broad spectrum of patients with SMA.
